GSK buys Mevacor OTC rights

Share this article:

GlaxoSmithKline will buy the rights to market Merck's cholesterol-lowering drug Mevacor (lovastatin) over-the-counter (OTC) in the US, pending FDA approval. Financial terms of the deal were not disclosed.

The deal is the second recent purchase by GSK of OTC rights to a treatment by another drugmaker. Earlier this year, GSK launched Alli, the OTC version of Roche's obesity treatment Xenical, purchased by GSK in 2004.
An FDA advisory committee is scheduled to meet Dec. 13 to review Merck's application to sell Mevacor in pharmacies in a once daily 20 mg for women 55 and older and for men at least age 45, GSK said.

Merck has twice failed to convince the FDA – once in 2000 and once in 2005 – that patients could safely use Mevacor without a doctor's prescription.

GSK's purchase of Mevacor's OTC rights “reinforces the commitment it has to this particular part of the business," said Mike Ward, an industry analyst at Nomura Code Securities, in a published report. “The over-the-counter usage of products that are switching from prescription to non-prescription use is a good area to be in. A lot of health authorities would like to switch more products, so that the costs fall on the patients.”

Nomura Code's Ward said he believed Mevacor had a better chance of winning approval this time around, but Mevacor's exact status as a non-prescription medicine is likely to be the subject of debate by regulators. The final outcome will determine the size of payments from GSK to Merck.

Mevacor lost US patent protection in 2001, with Merck and prospective marketing partner Johnson & Johnson trying to secure OTC status for the drug in the years that followed.

The UK became the first nation to approve an OTC statin in 2004, allowing the sale of a 10 mg version of simvastatin, which is marketed as Zocor Heart-Pro by Merck.

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...